THE DEAL, AT A GLANCE

Tempo Therapeutics

2/4 reviewed

Tempo Therapeutics

Tempo develops biosurgery products that build vascular tissue to strengthen and restore reconstructed soft tissue.

Tempo Therapeutics raised $15M Series B, announced 2026-09-16

01What it doesTempo develops biosurgery products that build vascular tissue to strengthen and restore reconstructed soft tissue.Source-grounded · automated review · Explore ↗

Checked 2026-10-06 · Review due 2026-10-13

Read supporting source ↗

Tempo’s leading biosurgery products solve…

02What happenedTempo Therapeutics raised $15M Series B, announced 2026-09-16From the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗

03Why it mattersIts work matters because engineered tissue could improve surgical repair outcomes in patients needing reconstruction.Interpretation · Explore ↗

Checked 2026-10-06 · Review due 2026-10-13

Read supporting source ↗

Using MAP technology, we are…

Click a part to explore its evidence. The image is supplied by the cited source.Original record source ↗

Tempo Therapeutics · Financing Record

Explore source-linked visual explanations for Tempo Therapeutics. Unsupported claims are withheld while source review continues.

Record 12428 · Recorded date: 2026-09-16